HDL Composition, Heart Failure, and Its Comorbidities

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2022 Mar 30

PMID 35350538

Authors

Ahmed Diab

Carla Valenzuela Ripoll

Zhen Guo

Ali Javaheri

Affiliations

Soon will be listed here.

Abstract

Although research on high-density lipoprotein (HDL) has historically focused on atherosclerotic coronary disease, there exists untapped potential of HDL biology for the treatment of heart failure. Anti-oxidant, anti-inflammatory, and endothelial protective properties of HDL could impact heart failure pathogenesis. HDL-associated proteins such as apolipoprotein A-I and M may have significant therapeutic effects on the myocardium, in part by modulating signal transduction pathways and sphingosine-1-phosphate biology. Furthermore, because heart failure is a complex syndrome characterized by multiple comorbidities, there are complex interactions between heart failure, its comorbidities, and lipoprotein homeostatic mechanisms. In this review, we will discuss the effects of heart failure and associated comorbidities on HDL, explore potential cardioprotective properties of HDL, and review novel HDL therapeutic targets in heart failure.

Citing Articles

Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review.

Javaheri A, Ozcan M, Moubarak L, Smoyer K, Rossulek M, Revkin J Heliyon. 2024; 10(16):e35916.

PMID: 39229539 PMC: 11369438. DOI: 10.1016/j.heliyon.2024.e35916.

Accumulating Sedentary Time and Physical Activity From Childhood to Adolescence and Cardiac Function in Adolescence.

Haapala E, Leppanen M, Lee E, Savonen K, Laukkanen J, Kahonen M J Am Heart Assoc. 2024; 13(6):e031837.

PMID: 38497441 PMC: 11010014. DOI: 10.1161/JAHA.123.031837.

Cardiac radiation improves ventricular function in mice and humans with cardiomyopathy.

Pedersen L, Valenzuela Ripoll C, Ozcan M, Guo Z, Lotfinaghsh A, Zhang S Med. 2023; 4(12):928-943.e5.

PMID: 38029754 PMC: 10994563. DOI: 10.1016/j.medj.2023.10.006.

Editorial: Lipids, lipoproteins and COVID-19.

Ozcan M, Zhu X, Zhang H, Javaheri A Front Cardiovasc Med. 2023; 10:1293249.

PMID: 38028441 PMC: 10646584. DOI: 10.3389/fcvm.2023.1293249.

Cholesterol efflux capacity is increased in subjects with familial hypercholesterolemia in a retrospective case-control study.

Sanz J, DAmuri A, Sergi D, Angelini S, Fortunato V, Favari E Sci Rep. 2023; 13(1):8415.

PMID: 37225774 PMC: 10209072. DOI: 10.1038/s41598-023-35357-4.

References

Malik P, Berisha S, Santore J, Agatisa-Boyle C, Brubaker G, Smith J . Zymosan-mediated inflammation impairs in vivo reverse cholesterol transport. J Lipid Res. 2011; 52(5):951-7. PMC: 3073469. DOI: 10.1194/jlr.M011122. View

Lecour S, Suleman N, Deuchar G, Somers S, Lacerda L, Huisamen B . Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation. 2005; 112(25):3911-8. DOI: 10.1161/CIRCULATIONAHA.105.581058. View

Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D . Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13:757-772. PMC: 5927356. DOI: 10.2147/CIA.S158513. View

Keul P, Sattler K, Levkau B . HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Fail Rev. 2007; 12(3-4):301-6. DOI: 10.1007/s10741-007-9038-x. View

Su W, Jiao G, Yang C, Ye Y . Evaluation of apolipoprotein M as a biomarker of coronary artery disease. Clin Biochem. 2008; 42(4-5):365-70. DOI: 10.1016/j.clinbiochem.2008.11.010. View

Feng Y, Van Eck M, Van Craeyveld E, Jacobs F, Carlier V, Van Linthout S . Critical role of scavenger receptor-BI-expressing bone marrow-derived endothelial progenitor cells in the attenuation of allograft vasculopathy after human apo A-I transfer. Blood. 2008; 113(3):755-64. DOI: 10.1182/blood-2008-06-161794. View

Haywood L, Ford C, Crow R, Davis B, Massie B, Einhorn P . Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009; 54(22):2023-31. DOI: 10.1016/j.jacc.2009.08.020. View

Sato Y, Takatsu Y, Kataoka K, Yamada T, Taniguchi R, Sasayama S . Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol. 2000; 22(12):811-3. PMC: 6655929. DOI: 10.1002/clc.4960221211. View

Hobson J, Rosenfeldt H, Barak L, Olivera A, Poulton S, Caron M . Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science. 2001; 291(5509):1800-3. DOI: 10.1126/science.1057559. View

10.

Kontush A, Chantepie S, Chapman M . Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol. 2003; 23(10):1881-8. DOI: 10.1161/01.ATV.0000091338.93223.E8. View

11.

Rye K, Barter P . Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008; 28(11):1890-1. DOI: 10.1161/ATVBAHA.108.173575. View

12.

Alonso A, Yin X, Roetker N, Magnani J, Kronmal R, Ellinor P . Blood lipids and the incidence of atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis and the Framingham Heart Study. J Am Heart Assoc. 2014; 3(5):e001211. PMC: 4323837. DOI: 10.1161/JAHA.114.001211. View

13.

Mishra M, Muthuramu I, Kempen H, De Geest B . Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension. Sci Rep. 2020; 10(1):8382. PMC: 7239951. DOI: 10.1038/s41598-020-65255-y. View

14.

Boren J, Chapman M, Krauss R, Packard C, Bentzon J, Binder C . Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020; 41(24):2313-2330. PMC: 7308544. DOI: 10.1093/eurheartj/ehz962. View

15.

Potocnjak I, Degoricija V, Trbusic M, Pregartner G, Berghold A, Marsche G . Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Sci Rep. 2017; 7:46642. PMC: 5394530. DOI: 10.1038/srep46642. View

16.

Frias M, Lecour S, James R, Pedretti S . High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT. 2013; 1(2):92-100. PMC: 3670301. DOI: 10.4161/jkst.19754. View

17.

Anand I, Latini R, Florea V, Kuskowski M, Rector T, Masson S . C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005; 112(10):1428-34. DOI: 10.1161/CIRCULATIONAHA.104.508465. View

18.

Elsoe S, Christoffersen C, Luchoomun J, Turner S, Nielsen L . Apolipoprotein M promotes mobilization of cellular cholesterol in vivo. Biochim Biophys Acta. 2013; 1831(7):1287-92. DOI: 10.1016/j.bbalip.2013.04.009. View

19.

Velagapudi S, Rohrer L, Poti F, Feuerborn R, Perisa D, Wang D . Apolipoprotein M and Sphingosine-1-Phosphate Receptor 1 Promote the Transendothelial Transport of High-Density Lipoprotein. Arterioscler Thromb Vasc Biol. 2021; 41(10):e468-e479. PMC: 8458249. DOI: 10.1161/ATVBAHA.121.316725. View

20.

Annoura M, Ogawa M, Kumagai K, Zhang B, Saku K, Arakawa K . Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology. 2000; 92(1):21-7. DOI: 10.1159/000006942. View